Recce Pharmaceuticals Ltd R327 progresses to stage 2 of SARS-CoV-2 Antiviral Screening Program at CSIRO
Following encouraging test results from stage1A and stage1B, RECCE® R327 received a qualified recommendation to advance to stage 2 of the program for...
John Prendergast Antiviral Screening Program Doherty Institute Viral Screening Program Anti Viral Screening Program Small Caps
Source: proactiveinvestors.com.au